Skip to main content
RESMED INC logo

RESMED INC — Investor Relations & Filings

Ticker · RMD LEI · 254900O2VD7IQ5OGI615 ASX Manufacturing
Open in API
Filings indexed 1,641 across all filing types
Latest filing 2025-05-08 Director's Dealing
Country AU Australia
Listing ASX RMD

About RESMED INC

https://www.resmed.com

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the management of sleep-disordered breathing, chronic obstructive pulmonary disease, and other respiratory conditions. The company’s primary product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel machines, and a variety of masks and accessories designed to improve patient adherence and comfort. ResMed distinguishes itself through its focus on digital health, offering integrated software platforms that enable remote patient monitoring and data-driven clinical insights for healthcare providers. Additionally, the company provides software-as-a-service (SaaS) solutions to support out-of-hospital care settings, including home health, hospice, and skilled nursing facilities, aiming to improve patient outcomes and reduce overall healthcare costs.

Recent filings

Filing Released Lang Actions
Notice of Proposed Sale Of Securities 3 pages 134.6KB
Director's Dealing Classification · 100% confidence The document is a Form 144 filing, which is a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. It details insider sales of securities by a director, including the number of shares sold, dates, and gross proceeds. This type of filing is specifically related to personal share transactions by company directors or executives, which matches the definition of Director's Dealing (DIRS). The document is not a financial report, earnings release, or regulatory announcement but a specific insider transaction notice.
2025-05-08 English
Notice of Proposed Sale of Securities 3 pages 134.6KB
Director's Dealing Classification · 100% confidence The document is a Form 144 filing, which is a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. It details the sale of securities by an insider (a director) including the number of shares, dates, and broker information. This type of filing is specifically related to insider transactions and personal share dealings by company directors or executives. It is not an annual report, earnings release, or any other financial report. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is the actual filing, not just an announcement or certification.
2025-05-08 English
Statement of Changes in Beneficial Ownership 2 pages 12.1KB
Director's Dealing Classification · 100% confidence The document is a Form 4 filed with the United States Securities and Exchange Commission (SEC). Form 4 is used to report changes in beneficial ownership of company securities by directors, officers, or significant shareholders. The text includes details of a transaction by Peter C. Farrell, a director, involving ResMed Inc. It reports the sale of shares and derivative securities. This type of filing is specifically related to insider transactions by company directors or executives. According to the filing definitions, this corresponds to 'Director's Dealing' (Code: DIRS). The document length and content confirm it is the actual report of the transaction, not just an announcement or certification. Therefore, the correct classification is DIRS with high confidence.
2025-05-08 English
Statement of CDIs on issue - RMD 3 pages 12.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4A - Statement of CDIs on issue' and provides detailed information about the number and class of CHESS Depositary Interests (CDIs) and other securities on issue for ResMed Inc. It includes monthly data for April 2025, changes in securities, and reasons for changes such as transfers, new share issues related to employee plans, and share repurchases. The document is a regulatory announcement related to securities on issue rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary. The document length is relatively short (3043 characters), and it is a formal statement of securities issued, which aligns with a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories like share issue announcements (SHA) or transaction in own shares (POS) because it covers multiple types of securities and changes comprehensively. Therefore, the best classification is Regulatory Filings (RNS).
2025-05-05 English
Form 10-Q for the Quarter Ended March 31, 2025 46 pages 576.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and explicitly states it is a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended March 31, 2025. It contains detailed unaudited condensed consolidated financial statements including balance sheets, statements of operations, comprehensive income, changes in equity, and cash flows, along with notes and management discussion sections. The length is substantial (15,000 characters) and includes actual financial data and analysis, not just an announcement or certification. Therefore, this document is a quarterly report (Interim / Quarterly Report). Q3 2025
2025-04-27 English
Resmed Announces Results for the Third Quarter of FY2025 10 pages 664.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025' and contains detailed financial data for the quarter ended March 31, 2025, including revenue, gross margin, income from operations, net income, earnings per share, and operating cash flow. It also includes a discussion of the quarter's results, business highlights, dividend program details, and condensed consolidated statements of operations with unaudited financial figures. The presence of comprehensive financial results and analysis for a fiscal quarter indicates this is a quarterly earnings report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-04-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.